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Abstract
To meet the requirements for rapid tumor growth, a complex array of non-neoplastic cells are recruited to the tumor
microenvironment. These cells facilitate tumor development by providing matrices, cytokines, growth factors, as well as
vascular networks for nutrient and waste exchange, however their precise origins remain unclear. Through multicolored
tissue transplant procedures; we have quantitatively determined the contribution of bone marrow-derived and adipose-
derived cells to stromal populations within syngeneic ovarian and breast murine tumors. Our results indicate that
subpopulations of tumor-associated fibroblasts (TAFs) are recruited from two distinct sources. The majority of fibroblast
specific protein (FSP) positive and fibroblast activation protein (FAP) positive TAFs originate from mesenchymal stem/
stromal cells (MSC) located in bone marrow sources, whereas most vascular and fibrovascular stroma (pericytes, a-SMA
+
myofibroblasts, and endothelial cells) originates from neighboring adipose tissue. These results highlight the capacity for
tumors to utilize multiple sources of structural cells in a systematic and discriminative manner.
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Introduction
Constituents of the tumor microenvironment can arise from two
major avenues: recruitment from nearby local tissue or systemic
recruitment from distant tissue via circulation. Though constitu-
tion will vary from tumor to tumor, very little is definitively
understood about the composition and origin of the host-derived
cellular milieu found within the various tumor microenvironments.
The most accessible option for tumor cells engaged in stromal
cell recruitment is to exploit resources in close proximity to the site
of tumor development. Dependent upon anatomical location,
these tissues are often rich sources of fibroblasts, pericytes and
vascular cells, as all cell types are critical for normal tissue function
as well.
Work by Udagawa et al. investigated the local cellular
contribution to the tumor microenvironment by transplanting
skin from a ubiquitously expressing green fluorescent protein
(GFP)-expressing mouse and establishing tumors in the subcuta-
neous space beneath the engrafted skin [1]. Their findings suggest
most of the tumor CD31
+ vessels are recruited from cells within
the nearby GFP
+ tissue using either a murine syngeneic lung
carcinoma or a xenogeneic osteosarcoma models. Additionally,
studies focusing on fibrosis leading to cancer development have
identified activated tissue resident cells responsible for excessive
extracellular matrix (ECM) production, such as pancreatic
stellate cells in pancreatitis that induce progression to pancreatic
cancer [2] or peribronchiolar and perivascular adventitial
lung fibroblasts that lead from lung fibrosis to lung cancer
development [3].
Though not as easily accessible as local tissue, accumulating
evidence has been presented suggesting recruitment from more
distant cell sources, such as bone marrow. In cases of rapid tumor
development, local cells may not be capable or in sufficient
numbers to meet expanding growth demands. Additionally, as
tumor vascular networks expand, access to systemically circulating
cells in the blood supply increases concurrently. Accordingly,
many findings have implicated extensive bone marrow contribu-
tion to the tumor microenvironment.
Both bone marrow and adipose derived endothelial and
mesenchymal progenitor cells have been isolated, cultured and
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tropic and tumor promoting capacity [4–8]. Furthermore, several
studies have addressed the contribution of bone marrow derived
cells to the tumor microenvironment utilizing transgenic mouse
models [9], and human bone marrow transplant patient tumor
samples [10]. The aforementioned studies suggest that bone
marrow derived cells contributed to less than 20% of the stroma
found in the tumor microenvironment, therefore, in our study, we
sought to address the origin(s) of the remaining percentage of
tumor associated stroma.
As hematopoietic cells, all immune cells originate from the bone
marrow, and the extensive contribution of immune cells in tumors
such as macrophages and lymphocytes has been well documented
[11–13]. In addition, our group recently demonstrated that bone
marrow derived mesenchyme contributes to vascular and
fibroblastic structures within the tumor microenvironment
[7,14]. Although these results are likely to be dependent on tumor
type and experimental conditions, evidence from us and others
clearly present several roles for non-immune bone marrow
derived cells in the tumor microenvironment. Additional evidence
for bone marrow originating circulating populations contributing
to tumor stroma is provided in a few studies that report the
existence of a circulating bone marrow derived endothelial
progenitor cells (EPCs) capable of contributing 10–50% tumor
associated endothelial cells in certain animal models [15–18].
Next, bone-marrow derived a-SMA+ myofibroblasts have
been cited to contribute between 0–30% of stromal isolated
fibroblasts within various tumor contexts [9,19–21]. Finally,
recent publications have proposed a bone marrow origin for
pericytes within the tumor vasculature [22–26]. These above
example suggest that bone marrow derived cells can con-
tribute to multiple stromal compartments in the tumor microen-
vironment.
Recruited tumor associated fibroblasts (TAFs) have been
identified as central participants in tumor remodeling and
structural matrix formation. These cells are often characterized
by increased expression of pathology-associated or ‘‘activated’’
fibroblast markers, fibroblast specific protein (FSP) and fibroblast
activation protein (FAP); increased expression of markers of
aggression and pro-tumorigenic growth factors; and markers of
fibrovascularization such as a-smooth muscle actin (a-SMA) and
desmin. The origin of TAFs is not well understood, but recent
evidence from our lab and others indicate bone marrow derived
mesenchymal stem cells (BM-MSC) are a source of TAFs
[7,27–29]. BM-MSC have been well characterized for their
tropism for inflammatory microenvironments such as wounded
tissue and tumors [30]. Within wounded tissue, MSC certainly
serve a beneficial role in aiding the healing process, however,
the role of MSC within the tumor microenvironment is not quite
as clear.
In this investigation, we sought to determine the origins of TAFs
and vascular stromal elements in the tumor microenvironment. By
performing a series of multi-colored bone marrow and adipose
tissue transplantations prior to tumor establishment, we were able
to quantitate endogenous contributions to these populations as
measured by multiple phenotypic markers, and determine the
tissue of origin of these cells. Our results demonstrate that bone
marrow mesenchyme, potentially as mesenchymal stem cells, is
recruited into tumors as FSP+/FAP+ TAFs, whereas the vascular
stroma (pericytes and fibrovascular structures) defined by
aSMA+/NG2+ TAFs as well as endothelial cells is recruited from
neighboring adipose tissue. These data suggest the recruitment of
two distinct subpopulations of TAFs each with a discrete tissue of
origin.
Results
Relative contribution of bone marrow-derived vs. local
resident tissue in ID8 ovarian tumors
In the first set of experiments, bone marrow from GFP
expressing mice was transplanted into lethally irradiated RFP
mice. Upon engraftment, as evidenced by .95% GFP expression
in the peripheral blood and the death of control mice not receiving
bone marrow, the mice received ID8 ovarian tumors (Figure S1).
Analysis of tumor sections revealed that GFP
+ and RFP
+
stromal cells (of non-tumor origin) comprised 23+/23% of cells
found within the tumor mass. These cells were found both around
the periphery and within the parenchyma of the tumor. Of the
stromal cells, 42+/29% were bone marrow-derived and 58+/
26% were non-bone marrow-derived, representing 10+/22%
and 14+/21% of the tumor bulk, respectively.
Next, we analyzed the tumor sections for phenotypic markers
generally associated with tumor associated fibroblasts (TAFs),
including aSMA, NG2, FAP and FSP. Interestingly, under our
experimental conditions, aSMA and NG2 expression overlapped
in pericytes lining the exterior of vessel walls and in some intra-
parenchyma fibrovascular structures. However, FAP and FSP
expression did not correspond to these cells and identified unique
populations of TAFs often found as isolated cells in infiltrating
stroma.
After quantitation of acquired images stained for bone marrow-
derived GFP
+ cells, host-derived RFP
+ cells, and markers of
stromal cells with Inform software, the origin of each recruited
stromal cell population was determined and there were statistically
significant (p,0.0001) differences between the origin within each
stromal marker group (Figure 1 and 2, Table 1). aSMA
+ cells
appeared to be largely non-bone marrow derived in origin (71+/
21%); however, a minor component of bone-marrow derived
aSMA
+ cells were detected representing 20+/27% the total
aSMA
+ stromal population. Similar to aSMA staining patterns,
NG2+ populations were nearly identical in tissue origins: 73+/
25% originating from non-bone marrow tissue and 21+/28%
from bone marrow (Figure S2).
In contrast to aSMA+ and NG2+ pericytic and myofibroblastic
populations, fibroblastic FAP
+ and FSP
+ cells were more heavily
recruited from the bone marrow than from the neighboring
adipose tissue (p,0.0001). In particular, 72+/25% FAP
+ cells
were bone marrow in origin while only 16+/211% originated
from non-bone marrow tissues. Correspondingly, 63+/26% and
23+/28% of FSP+ cells arose from bone marrow and non-bone
marrow tissues, respectively (Table 1).
CD31+ endothelial cells were also quantitated in these analyses.
Surprisingly, nearly every vessel (p,0.0001) was of non-bone
marrow origin (91+/26%), and only a minority of endothelial
cells were possibly bone marrow-derived (2+/21%). As a positive
control, macrophages were also measured and expected to be
100% bone marrow derived if the transplantation were complete.
As anticipated, F4/80+ cells were mostly (p,0.0001) of bone
marrow origin, quantified as 91+/26% of all macrophages found
in the tumor microenvironment. Conversely only 1+/21% of F4/
80+ cells were non-bone marrow derived (Table 1).
Contribution of endogenous bone marrow derived MSC
to the tumor microenvironment
We hypothesized BM MSC may be the cell source of bone
marrow derived stromal contribution to the TAF population.
Therefore, contribution of BM MSC to the endogenous tumor
microenvironment was evaluated by transplantation of both
prospectively isolated and in vitro isolated and expanded BM
Quantification of Tumor Associated Stoma
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2CD31
2Sca-1+ cells were
prospectively isolated from the bone marrow cells of an RFP
expressing mouse. This population was reported by Short et al. to
contain all MSC activity from the bone marrow [31].
Additionally, mMSC were isolated by in vitro plastic adherence.
Both populations were verified to express a MSC phenotype and
to differentiate into bone, fat and cartilage under appropriate
culture conditioning (Figure S3).
RFP+ cells were detected in the tumor microenvironments of
both prospectively isolated and in vitro cultured BM MSC
transplant recipients (Figure 3). In all samples, recruited RFP+
cells were most frequently identified around the tumor periphery
as isolated cells with no apparent vascular or fibrovascular
structural formation. The spatial organization was similar to that
of FAP+ and FSP+ detected cells in the whole bone marrow
transplant experiments sections. Correspondingly, .75% of both
prospective and in vitro isolated BM MSC populations (the sorted
RFP+ cells and in vitro RFP+ MSC) that were recruited to the
tumor microenvironment co-expressed FAP and FSP (Figure 3). In
accord with the apparent lack of RFP+ fibrovascular structures,
most RFP+ populations were negative for a-SMA and NG2,
though a few positive cells could be detected in each sample. None
of the RFP+ transplanted populations co-stained with CD31,
indicating they did not contribute to the endothelial compartment
of the tumor microenvironment.
Contributions of adipose-derived stromal cells in E0771
breast tumors
We next hypothesized that cells in neighboring adipose tissue
may account for non bone marrow tissue contribution to TAFs
(pericyte and myofibroblasts) and/or endothelial populations.
Furthermore, we sought to verify this non bone marrow tissue
contribution in another tumor model and examined E0771 breast
tumors. Therefore, mice were subcutaneously transplanted with
GFP+ adipose tissue, and after 10 days to facilitate engraftment,
E0771 murine breast cancer cells were injected adjacent to
Figure 1. Bone marrow tissue contributions to tumor stromal elements. Lethally irradiated RFP+ mice were reconstituted with GFP+ bone
marrow (n=3). After engraftment, ID8 cells were injected subcutaneously. 5 weeks later, tumors were harvested, and sections were analyzed for a-
SMA, NG2, FAP, FSP, CD31, and F4/80 co-staining with GFP+ bone marrow derived cells or RFP+ non bone marrow derived cells. (A&B) Red arrows
represent co-staining of GFP+ bone marrow derived cells with FAP, FSP or F4/80. Representative images are shown for 2 separate animals.
doi:10.1371/journal.pone.0030563.g001
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tumor and surrounding adipose tissues were removed and
analyzed.
GFP staining of the transplanted adipose tissue indicated the
presence of successfully engrafted vascularized adipose tissue
bearing typical adipocyte morphology (Figure 4). GFP+ cells were
found throughout adjacent, infiltrating tumor tissue but remained
proximal to the site of transplanted adipose tissue (Figure S4).
Tumor tissue distal to GFP+ adipose tissue displayed no evidence
of recruited GFP+ stromal cells.
When quantified, it was determined that the transplanted
adipose tissue contributed mainly to a-SMA, NG2, and CD31
endothelial cell populations (Figure 5 A&B). Specifically, of the
recruited GFP+ cells, 18+/22% gave rise to CD31+ endothelial
cells. 55+/23% and 58+/25% of GFP+ cells within the tumor
tissue co-stained with a-SMA and NG2, respectively (Table 2).
Conversely, only 7+/23% of the adipose-derived cells were also
positive for FSP, and an even smaller percent co-localized with
FAP expression (2+/21%; Figure 5 C&D; Table 2). As a negative
control, staining for macrophage marker F4/80 revealed 2+/21%
co-localization with GFP expressing cells.
Discussion
In this work, we quantified the a-SMA+, NG2+, FAP+, FSP+,
CD31+, and F4/80+ stromal contributions to the tumor
microenvironment. Many previous reports have investigated
various bone marrow derived cell recruitment to tumors, however,
these studies have focused on a single marker or a single stromal
element and few attempted quantitation of these contributions
[1,6,9,20,24,32,33]. An elegant series of experiments by Quante
et al. revealed the incorporation of bone marrow derived aSMA+
cells amounting to about 20% of the tumor stroma [9], similar to
our own results where we observed a far greater contribution of
Figure 2. Non-bone marrow tissue contributions to tumor stromal elements. Lethally irradiated RFP+ mice were reconstituted with GFP+
bone marrow (n=3). After engraftment, ID8 cells were injected subcutaneously. 5 weeks later, tumors were harvested, and sections were analyzed for
a-SMA, NG2, FAP, FSP, CD31, and F4/80 co-staining with GFP+ bone marrow derived cells or RFP+ non bone marrow derived cells. (A&B) Yellow
arrows represent co-staining of RFP+ non-bone marrow derived cells with a-SMA, NG2 or CD31. Representative images are shown for 2 separate
animals.
doi:10.1371/journal.pone.0030563.g002
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bone marrow derived source.
When sub-divided, quantitative results of stromal marker
expression indicated that the majority of FSP+, FAP+ and F4/
80+ stromal populations found within the tumor microenviron-
ment originated from the bone marrow (p,0.01). Conversely,
most a-SMA, NG2, and CD31 expressing cells were of a non-bone
marrow, adipose tissue-derived origin (p,0.01). While a-SMA,
NG2, FAP, and FSP have often been grouped together as
collective markers for TAF and/or myofibroblasts [7,27,29], in
this work it is apparent these markers designate disparate
mesenchyme populations with distinct tissues of origin. These
findings are in accord with reports from Sugimoto et al. indicating
heterogeneity within the fibroblast compartment of the tumor
microenvironment [34]. In examining syngeneic pancreatic and
breast tumors, Sugimoto reported significant overlap between a-
SMA and NG2 antigens and minimal overlap between a-SMA/
NG2 and FSP, concluding that FSP identifies a unique population
of fibroblasts within the tumor stromal component. Corresponding
distinctions between FSP and a-SMA expression have also been
noted in examinations of fibrotic glomerulonephritis [35].
The bone marrow-derived tumor associated stromal compo-
nents defined by FAP and FSP expression could be largely
characterized as isolated cells, lacking organization near the
periphery of the tumor. The primary functions of calcium binding
protein FSP and dipeptidyl peptidase FAP revolve around
promoting migration, altering adhesive properties and remodeling
the extracellular matrix [36–38]. These properties are most
frequently utilized at sites of expansion and metastasis along the
periphery of tumor development, which is consistent with our
observations.
Conversely, non-bone marrow derived cells were often found in
clusters, demonstrating organization into vascular and fibrovascu-
lar-like structures. In our model, a-SMA and NG2 expression
localized to cells organized into vessel-like formations, correspond-
ing to pericytic locations throughout the tumor. These spatial
distribution findings are consistent with a report from Udagawa et
al. indicating a similar pattern in recruited bone marrow cells to
Lewis lung carcinoma tumors [1]. In our work herein, fairly equal
distribution (p.0.05) of bone-marrow versus non-bone marrow
derived stroma was observed as a total when looking at GFP+
versus RFP+ stroma within the tumor microenvironment.
One very striking result of the transplant experiments was a
notable lack of bone marrow originating CD31+ endothelial cells.
The existence of a circulating bone marrow-derived endothelial
progenitor (BM EPC) has been a topic of controversy for the past
decade, dating back to its initial description by Asahara and
colleagues in 1997 [39]. BM EPC have been reported to
contribute significantly to tumor vasculature in many investiga-
tions [6,32,33]. However, other studies have revealed no
contribution of the bone marrow to neovasculature in tumors
[18,24,40,41]. It is likely that the array of conflicting results has
arisen from a multitude of experimental conditions differing in
each investigation. In fact, work by Monsky et al. illustrated this
point. In their study, the degree of bone marrow derived
endothelial progenitor cell incorporation in mammary tumor
vasculature varied from ,4% when implanted in the fat pad or
subcutaneous space to nearly 60% when implanted in the brain
[42]. Their results also varied greatly among different tumor types
and mouse strains. Our results are in accord with experiments in
this study utilizing subcutaneously implanted syngeneic C57Bl/6
lung carcinoma and melanoma tumors where minimal bone
marrow derived endothelial cell contributions were noted.
However, under alternative conditions such as orthotopic
implantation or a different time course, the outcome may have
been different.
In the next set of experiments, we examined the potential of
prospectively isolated BM-MSC to give rise to the bone marrow
derived stromal components in the tumor microenvironment.
Though publications utilizing prospectively isolated murine MSC
are rare, a recent investigation has identified prospective these cells
within the Lin
2CD31
2Sca-1
+ fraction of bone marrow mononu-
clear cells [31]. Similar experiments have been done based on
aSMA+ fractionation of MSC to reveal the contribution of
aSMA-expressing MSC to the tumor stroma in gastric cancer [9].
We found transplanted cells from this population as well as BM
MSC isolated by traditional methods of plastic adherence and in
vitro expansion were both recruited to the tumor microenviron-
ment. Flow cytometric analysis of peripheral blood and whole
bone marrow from transplanted animals showed full donor
chimerism (,1% host-derived cells in the peripheral blood).
Immunofluorescence of adipose tissue sections, however, did show
the presence of prospective and in vitro expanded BM MSC. Since
MSC are resistant to radiation, as evidenced by their persistence
after a lethal dose in our hands and previous reports [43,44], these
cells are still occupying the bone marrow MSC niche, and
transplanted MSC may not have a place to engraft within that
environment. Adipose tissue is known to contain what is termed as
adipose derived stem cells (ASC) or adipose derived MSC, which
appear similar to BM MSC in many regards [45–48]. Addition-
ally, this tissue readily expands, perhaps providing new potential
MSC niches [49].
Both prospective and in vitro isolated MSC populations were
found at similar rates of incidence within the tumor microenvi-
ronment, typically localized to the tumor mass periphery. 64–76%
of recruited BM MSC were identified in stromal locations, and
only 23–35% were found within the tumor parenchyma.
Correspondingly, co-staining with stromal markers revealed
similar phenotypes within the tumor microenvironment. Most of
these cells were also positive for FSP and FAP. A minority of
recruited cells in each group was found to express a-SMA and
NG2, and all RFP+ recruited cells were negative for CD31 and
F4/80. These results indicate that in vitro expanded BM MSC and
Lin
2CD31
2Sca-1
+ prospective BM MSC are a potential source of
bone marrow derived FAP+ and FSP+ stromal cells recruited to
the tumor microenvironment.
Table 1. Quantitative analysis of the origin of stromal
elements.
Stromal Marker Bone marrow derived Non-bone marrow derived
a-SMA* 20+/277 1 +/21
NG2* 21+/287 3 +/25
FAP* 72+/251 6 +/211
FSP* 63+/262 3 +/28
CD31* 2+/219 1 +/26
F4/80* 91+/261 +/21
Table representing the quantitative analysis of the origin of stromal elements.
a-SMA+, NG2+,F A P +, FSP+, CD31+, and F4/80+ populations within the tumor
microenvironment were analyzed for GFP and RFP co-staining. Numbers
represent the percent of the indicated stromal population that were bone
marrow derived (GFP+) or non-bone marrow derived (RFP). The percentages
were averaged among 3 different animals and are displayed as average +/2
standard deviation. P-values (*p,0.0001) were obtained by Student’s t-test, N
represents total number of nuclei per cluster of images (180,000).
doi:10.1371/journal.pone.0030563.t001
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pericytes and endothelial cells not recruited from the bone
marrow, we next hypothesized these elements may be arising
from neighboring adipose tissue. Obesity has been determined as a
predisposing factor for cancer development and is associated with
poor prognosis of certain cancer types [50]. Since obesity arises
Figure 3. BM MSC contribution to the tumor microenvironment. Prospectively isolated and in vitro isolated MSC (RFP+) were combined with
whole marrow and transplanted into lethally irradiated mice (n=3 for each of the 2 groups). After engraftment, ID8 cells were subcutaneously
injected. After 5 weeks of tumor groups, sections from harvested tumors were analyzed for RFP+ cells. (A) Representative images are shown for RFP
co-staining with FAP and FSP as indicated by the white arrows in the merged images. There is no co-staining between RFP+ cells and a-SMA. (B)
Scores were assessed for the relative percentage of RFP+ cells co-staining with each stromal marker.
doi:10.1371/journal.pone.0030563.g003
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proposed that this tissue may play a significant role in tumor
initiation and/or progression [4,51,52]. WAT is composed of
many cell types, including adipocytes, pre-adipocytes, endothelial
cells, pericytes and an assortment of stromal cells [49]. Precursors
from WAT have been shown to contribute to in vitro vessel
formation and stabilization [48] as well as in vivo revascularization
of damaged skeletal muscle [53]. Within the stromal fraction of
WAT, progenitors with a similar phenotype, proliferative rate and
differential capacity to BM MSC have been identified [47,54].
Recently, exogenous addition of these progenitors, referred to as
adipocyte stem or stromal cells (ASC), has been shown to enhance
tumor progression in syngeneic and xenogeneic models [4,8].
Additionally, adipose tissue transplanted in a nude mouse was
shown to be recruited to developing tumors 2cm away from the fat
location [4,8]. Taken together, these findings suggest a role for
adipose-derived cells in the tumor microenvironment, though their
participation has not been fully investigated.
In our studies, GFP+ adipose tissue was successfully engrafted as
indicated by vascularization, typical adipocyte morphology and
size to control adipose tissue specimens, as previously described
[55]. Interestingly, GFP+ adipose-derived cells visualized within
the tumor bulk were not uniformly distributed; only tumor tissue
within close proximity to the transplanted adipose tissue (,5 mm)
contained GFP+ cells. Parts of the tumor distal (.5 mm) to the site
of GFP+ adipose tissue transplantation were negative for GFP+
recruited stromal components. These findings are in accord with
adipose tissue transplantation results reported by Zhang et al.,
Figure 4. Engrafted GFP+ adipose tissue is locally recruited into the tumor microenvironment. GFP+ adipose tissue was subcutaneously
implanted into wild type mice (n=3). After engraftment, E0771 cells were subcutaneously injected. Two weeks later, sections of resected tumors and
adjacent adipose tissue were analyzed for GFP expression. Analysis revealed engrafted adipose tissue with normal morphology. Recruited GFP+
adipose derived cells remained in close proximity to the transplanted adipose tissue. White arrows in the montage image indicate adipose-derived
tumor stroma participants.
doi:10.1371/journal.pone.0030563.g004
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adipose tissue, transplanted adipose derived cells traveled much
greater distances (.2 cm). C57Bl/6 mice utilized in our model did
contain endogenous adipose tissue, and it is likely recruitment of
endogenous adipose derived cells could account for many stromal
components distal to the site of GFP+ adipose tissue transplan-
tation. Both of these models support the hypothesis of a role for
adipose-derived cells in the tumor microenvironment. However,
the difference seen between them suggests that tumor behavior is
largely dictated by environmental context. Models with low levels
of endogenous adipose tissue may not accurately reflect the disease
seen in the average human, since nearly 70% of adults in the U.S.
are classified as overweight or obese [56].
Quantitation of GFP+ recruited adipose derived cells revealed
that most (50–60%) of these cells were positive for a-SMA and
NG2. The location and structural formation of these double
Figure 5. Stromal marker expression of recruited GFP+ adipose derived cells. GFP+ adipose-derived cells displayed (A & B) a high degree of
overlap in expression of CD31, a-SMA, and NG2 as indicated by the white arrows in the merged column and (C & D) minimal overlap with FAP, FSP,
and F4/80. Representative images are shown for 2 separate animals.
doi:10.1371/journal.pone.0030563.g005
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nearly 20% GFP+ adipose derived cells were positive for CD31
and formed vessel structures within the tumor parenchyma.
Varying reports in the literature have indicated conflicting data
concerning the origins of tumor associated stromal cells
[1,7,15,20,25,57,58]. It is likely these discrepancies stem from
variations in experimental models and design. As mentioned
previously, Monsky and colleagues described a ,4% incorpora-
tion of bone marrow derived endothelial progenitors when a
breast tumor was implanted in or near adipose tissue, yet this
number rose to 60% when the same tumor was located in the
brain [42].
These results along with our own would suggest that tumors will
preferentially recruit stromal cells from nearby tissue such as fat
when it is available. However, when unavailable, tumors may
resort to recruitment from alternate and often more distant
sources. The term ‘‘tumor associated fibroblast’’ has been used to
describe cell populations identified by a variety of phenotypic
markers [7,27–29]. Though TAFs have been collectively grouped
under the same generic nomenclature, our results as well as the
results of others [34] indicate this is a heterogeneous popu-
lation with discreet subpopulations. Our results further indicate
different TAFs have distinct tissues of origin. In our model, we
propose that when available, tumors will recruit vascular
endothelial cells and fibrovascular TAFs or pericytes as defined
by aSMA and NG2 from nearby, local, adipose tissue (Figure 6).
However these locally recruited cells cannot meet the tumor’s
tissue remodeling needs as it expands and grows. At this point,
another subpopulation of TAFs is recruited systemically from the
bone marrow. Our data confirm that BM MSC are a source of
bone-marrow derived cells and once they are in the tumor
microenvironment, a subset will express pathological disease
associated markers FSP and FAP. These proteins mark the
transformation of a recruited fibroblastic cell into a pathological
cell which aids in the promotion of tumor extracellular matrix
remodeling, motility, and metastasis.
Our model suggests that the basis for tumor stroma heteroge-
neity arises from the disparate origin of the stromal components,
however differing tumor types, modes of tumor establishment, age
of the host and time of evaluation are likely to alter the
microenvironment composition. For example, bone marrow
derived cells may contribute more heavily to pericyte and/or
endothelial populations when local cells cannot meet the growth
demand of the tumor vasculature. As we have learned in recent
years, the tumor is composed not only of transformed cancerous
cells, but also normal cells recruited to aid in tumor growth and
propagation. The role of these key players and their interactions in
the tumor microenvironment reveals a new paradigm for cancer
treatment by targeting the ‘‘soil’’ instead of only the ‘‘seed.’’ The
identification of this cellular milieu is the first step in unraveling
the complex interactions between tumor and host cells and
identifying possible areas for intervention. The models we have
developed have not only revealed insights to the composition of
the tumor microenvironment but also provide a platform on which
candidate drugs aimed at disrupting tumor-stroma interactions
may be tested.
Materials and Methods
Cell Culture
ID8 C57Bl/6 murine ovarian tumor cells were a generous gift
of Dr. Kathy Roby (University of Kansas Medicial Center) [59].
The cells were maintained in DMEM supplemented with 10%
FBS, penicillin-streptomycin, and L-glutamine. The E0771
C57Bl/6 murine mammary tumor cells (a kind gift from Dr.
F.M. Sirotnak, Memorial Sloan Kettering, New York, NY) were
maintained in RPMI 1640 supplemented with 10% FBS,
10 mmol/L HEPES, penicillin-streptomycin, and L-glutamine.
Table 2. Recruited adipose derived cell expression of stromal
markers.
Stromal Marker % fat derived cells co-stained
a-SMA* 56+/25
NG2* 58+/28
FAP* 2+/21
FSP* 7+/25
CD31* 18+/23
F4/80* 2+/21
GFP+ cells recruited from local adipose tissue were quantified within the tumor
stroma for co-expression of stromal markers. Numbers presented represent the
percentage of the recruited GFP+ cells that were also positive for the indicated
marker. The percentages were averaged among 3 different animals and are
displayed as average +/2 standard deviation. P-values were obtained by
Student’s t-test, N represents total number of nuclei per group (180,000).
doi:10.1371/journal.pone.0030563.t002
Figure 6. Model of stromal recruitment. A tumor is composed of
not only cancer cells, but also recruited host-derived cells. Our model
suggests that the majority of pericytes (NG2+ and a-SMA+) and
endothelial cells (CD31+) are recruited from local tissue, such as local
adipose tissue. FAP+ and FSP+ fibroblastic cells involved in extracellular
matrix remodeling are recruited from host bone marrow populations,
such as BM MSC.
doi:10.1371/journal.pone.0030563.g006
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Murine MSC (mMSC) were isolated as described previously
[14]. Briefly, femurs of 2-month-old C57Bl/6 mice (Harlan Labs,
ME) were collected, dissected into small fragment, then placed into
a sterile mortar and crushed using a sterile pestle. Bone marrow
was reserved, and bone fragments were incubated with Type I
collagenase at 37uC. After incubation, liberated cells were
combined with reserved marrow and plated in aMEM with
20% FBS in a 180 cm
2 dish. After five days, the plate was washed
to remove non-adherent cells. Adherent cells were retrieved by
trypsinization and immunodepleted of granulo-monocytic cells
using a biotinylated antibody against CD11b (BD Biosciences,
San Jose, CA), and streptavidin-coated microbeads from
Miltenyi Biotec (Auburn, CA) according to the manufacturer’s
instructions. After immunodepletion, the remaining cells were
plated in fresh media, and within 3 additional days, fibroblast-like
colonies were observed. Medium was changed two to three times a
week and cell density was maintained between 2,000 and
6,000cell/cm
2.
Prospective MSC Isolation
Prospective MSC were isolated as previously described with
some modification [31]. Whole bone marrow was collected from
C57Bl/6 mice and enriched for Sca-1+ cells with MACS
microbeads, as recommended by the manufacturer (Miltenyi
Biotec, Auburn, CA). Post enrichment, cells were stained with
APC conjugated rat anti mouse hematopoietic lineage antibodies
(CD3, CD4, CD5, CD8, CD11b, Gr-1, B220, and Ter-119) and
APC conjugated rat anti-mouse CD31 (BD Biosciences, San Jose,
CA). Fluorescence activated cell sorting was then performed to
isolate Lin2CD312Sca-1+ cells on a BDFACS Aria (Becton
Dickenson, San Jose, CA).
Animals
Transgenic C57Bl/6 mice expressing either GFP under the
control of the ubiquitin promoter, RFP under the control of the
chicken beta actin promoter or LacZ under the control of the
ROSA26 promoter were purchased from Jackson Labs, and bred
in house to maintain colonies. Mice were utilized for experiments
between 8 and 12 weeks of age. All mice were housed and treated
in accordance with institutional standards. This study was
approved by the MD Anderson Institutional Review Board and
Institutional Animal Care and Use Committee approved protocol
(100510632).
Whole Bone Marrow Transplantation
Whole marrow was isolated from the tibia, femur, and iliac
crest, as detailed in the ‘‘Isolation and propagation of murine
MSC’’ section above. Recipient C57Bl/6 mice were lethally
irradiated with 10 Gy 4 hours before reconstitution. 10
7 donor
whole marrow cells suspended in 100 ml PBS were then tail vein
injected (IV) into irradiated mice. Control animals received PBS
injections. Within 2–3 weeks, control animals died while
transplanted animals survived and displayed 99% donor-derived
cells in the bone marrow.
MSC Transplantation
MSC were isolated prospectively and in vitro as described above
from an RFP+ mouse. 100,000 of each population was combined
with 10
7 whole marrow cells from a LacZ+ mouse and
transplanted into a lethally irradiated GFP+ recipient as described
in whole marrow transplantation.
Adipose tissue Transplantation
Adipose tissue transplants were performed as described
previously [55]. Donor fat pads were removed from the intra-
abdominal perigonadal area of GFP+ mice. The fat pads were
sliced into 100–150 mg pieces and stored in warm PBS until the
time of transplant. The right dorsal side of anesthetized mice was
shaved and cleaned with alcohol. Fat slices were placed just below
the skin in the subcutaneous space, and incisions were closed with
metal clips. Clips were removed when the wound was resolved 3–5
days after transplant.
Tumor Administration
After transplantation procedures were performed and tissue
engraftment was verified, tumor cells were subcutaneously injected
into the upper hind limbs in the case of bone marrow
transplantation experiments. Tumor cells were subcutaneously
injected adjacent to the site of adipose tissue transplantation on the
backs of recipients. ID8 tumors were established and harvested 5
weeks after injection of 10
7 ID8 tumor cells. E0771 tumors were
established and harvested 2 weeks post injection of 5610
4 E0771
tumor cells.
Flow Cytometry
Cells were resuspended in PBS supplemented with 2% FBS (10
6
cells/100 ml/staining reaction). 1 mg of each antibody was added
to the cell suspension and incubated at 4uC for 30 minutes.
Labeled cell populations were then analyzed on an LSR II flow
cytometer (Becton Dickenson, San Jose, CA) with FACS Diva
software. Sample acquisition was accompanied with use of control
unstained, single color stained and isotype controls to determine
the appropriate voltages, compensations, and positioning of gates
for data acquisition.
Immunofluorescence
Paraffin embedded sections were rehydrated and deparaffi-
nized. Primary antibodies used for fibroblast detection were rabbit
anti-fibroblast activation protein (abcam) and rabbit anti-S100A4/
fibroblast specific protein (Dako). Myofibroblasts were identified
by mouse IgG2a anti-a-smooth muscle actin (abcam) and rabbit
anti-NG2 (Chemicon). Antibodies for endothelial and macrophage
detection were rabbit anti-CD31 (abcam) and F4/80 (abcam),
respectively. Secondary antibodies conjugated to AlexaFluor350,
AlexaFluor488, AlexaFluor594, and AlexaFluor647 fluoro-
chromes (Invitrogen) were used for primary antibody detection.
Nuclei were identified by DAPI staining.
Image Acquisition and Data Analysis
Stained slides were mounted with Dako Anti-fade mounting
medium (Dako) and visualized on an Olympus IX51. Multi-
spectral data was acquired with Nuance camera and imaging
software. Data analysis was performed with Inform software
(Figure 3). First, regions of interest were defined on 4–6 images,
and the recognition software was trained to classify all images.
Then, nuclei were located based on DAPI fluorescence and
defined nuclear size parameters within the classified area of
interest. Next, cytoplasm was drawn around the identified nuclei
as described by user-defined parameters, and then fluorescence
data in pixels was quantified for each nucleus and cytoplasm for
each cell. Data was exported into excel where nuclear and
cytoplasmic signals were summed to give per cell quantitation of
pixel count for each fluorochrome. Numerical cutoffs based on
isotype controls were used to define Alexa fluor 488+, Alexa fluor
594+, and double positive cell populations, and each image was
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were quantitated and averaged at 3 different depths within the
tumor, which were in turn averaged to give a final percent across
each tumor. 3 tumors were analyzed in this manner per
experimental group.
Statistical Analysis
Results are reported as means +/2 standard error. P-values
were obtained by Student’s t-test. N was number of nuclei per
group based on dapi staining and was on average 60,000 per
animal and 180,000 stromal marker group based on 3 replicates
per group.
Supporting Information
Figure S1 Bone marrow transplant experimental de-
sign. Bone marrow from a GFP+ mouse was transplanted into a
lethally irradiated RFP+ mouse. After 4 weeks, engraftment is
verified by .99% GFP positivity in peripheral blood as well as
bone marrow. At this time, ID8 cells are injected subcutaneously.
After 5 weeks of tumor development, the tumor is resected and
analyzed for recruited bone marrow (GFP+) and non bone
marrow (RFP+) host derived cells in the tumor microenvironment.
(TIF)
Figure S2 RFP+ Bone marrow and GFP+ non-bone
marrow tissue contributions to the tumor microenvi-
ronment. To verify results, the converse bone marrow
transplantation experiment was performed in which lethally
irradiated GFP+ mice were reconstituted with RFP+ bone marrow
(n=3). After engraftment, ID8 cells were injected subcutaneously.
5 weeks later, tumors were harvested, and sections were analyzed
for a-SMA, NG2, FAP, FSP, CD31, and F4/80 co-staining with
(A) RFP+ bone marrow derived cells co-stain with FAP, FSP and
F4/80 as depicted by the yellow arrows in the merge column. (B)
GFP+ non bone marrow derived cells co-stain with a-SMA, NG-2
and CD31 as identified by the red arrows in the merge column.
Representative images are shown from 1 animal.
(TIF)
Figure S3 Characterization of MSC. mMSC were isolated
by (A) in vitro plastic adherence or (B) prospective sorting of Lin2
CD312 Sca-1+ cells. Cells from both populations were placed in
culture and analyzed for bone, fat, and cartilage differentiation
potentials as evidenced by Alizarin Red S, Oil Red O, and Alcian
Blue staining, respectively. They were also phenotypically
examined for CD44, Sca-1, CD140b, and CD106 expression
and a lack of CD45, CD11b, and CD31.
(TIF)
Figure S4 Engrafted GFP+ fat is locally recruited into
the tumor microenvironment. GFP+ fat was subcutaneously
implanted into wild type mice (n=3). After engraftment, E0771
cells were subcutaneously injected. Two weeks later, sections of
resected tumors and adjacent fat were analyzed for GFP
expression. Analysis revealed engrafted fat with normal morphol-
ogy. Recruited GFP+ fat derived cells remained in close proximity
to the transplanted fat.
(TIF)
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